{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06741644","nct_id":"NCT06741644","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06741644. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be administered escalating doses of CS2009.","label":"Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants will be administered the recommended dose(s) of CS2009 with or without chemotherapy according to dose-escalation data.","label":"Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-01","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":800,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"CS2009","otherNames":[],"type":"DRUG"},{"name":"CS2009","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Leucovorin","otherNames":[],"type":"DRUG"},{"name":"5-FU","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-20","lead_sponsor":"CStone Pharmaceuticals","official_title":"A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"[Dose Escalation] Maximum tolerated dose (MTD) of CS2009","timeFrame":"Cycle 1 (Up to 21 Days)"},{"measure":"[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009","timeFrame":"Cycle 1 (Up to 21 Days)"},{"measure":"[Dose Escalation] Number of participants with adverse events (AEs)","timeFrame":"Up to approximately 2 years"},{"measure":"[Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2025-02-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06741644"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06741644"}